Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of carboplatin and gemcitabine to standard therapy in breast cancer
IRCT2017100136491N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of carboplatin and gemcitabine in breast cancer, sponsored by Shiraz University of Medical Sciences. Started Nov 2017; status: completed.
02
Drugs
carboplatingemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT2017100136491N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017100136491N1.